ライフサイエンスコーパス: TSLP

1 TSLP activates multiple immune cell subsets expressing t

2 TSLP expression was localized to the airway epithelium,

3 TSLP induced mitogen-activated protein kinase kinase (ME

4 TSLP production and dermatitis induced by alkalinization

5 TSLP was synergistically induced in epithelial cells by

6 TSLP, IFN-lambda and LDH were not increased by allergen

7 We also examined the genetic effects of 2 TSLP functional single nucleotide polymorphism (SNPs) on

8 minally with IL4/KIF3A (P = .019; OR, 1.25); TSLP's association persisted (P = 4.7 x 10(-5); OR, 1.37

9 The effects of cysLTs, PGD2, IL-33, IL-25, TSLP, and IL-2 alone or in combination on ILC2s were def

10 cells, type 2 innate lymphoid cells, IL-33, TSLP) that have important roles in the development of al

11 IL-4, TSLP, IL-17A, EPO activity, total cell count and specifi

12 y has been associated with variants at 5q22 (TSLP) and 2p23 (CAPN14), indicating roles for allergic s

13 nct genetic susceptibility elements at 5q22 (TSLP) and 2p23 (CAPN14).

14 pressed skin cancer development in mice in a TSLP-dependent manner.

15 +) cells) and IL-13(+) ILC2s, emergence of a TSLP receptor-positive IL-9(+) ILC2 population, and an i

16 Recent data suggest that a TSLP/ILC axis may mediate steroid resistance in asthma.

17 ILC2 proliferation and activation through a TSLP-dependent mechanism in a murine model and suggest t

18 arly induced IL-13-producing ILC2s through a TSLP-dependent mechanism.

19 However, knowledge about TSLP receptor expression and functional consequences of

20 In addition, TSLP and IL-33 synergistically promoted group 2 innate l

21 uncated products, TSLP (residues 29-124) and TSLP (131-159).

22 ine IL-10, TGF-beta, IL-4, IL-13, IL-22, and TSLP secretion and SOCS1/SOCS2/SOCS3 induction.

23 The cytokines IL-25 and TSLP, similarly promote proinflammatory tissue responses

24 We reasoned that IL-33 and TSLP expression are also induced by RV infection in imma

25 nfection of 6-d-old mice increased IL-33 and TSLP protein abundance.

26 Administration of intranasal IL-33 and TSLP was sufficient for mucous metaplasia.

27 s are linked to release of IL-25, IL-33, and TSLP by epithelial cells; these cytokines, especially IL

28 hanced the effect of PGD2, IL-25, IL-33, and TSLP, resulting in increased production of type 2 and ot

29 among the innate cytokines IL-25, IL-33, and TSLP.

30 IL-7 and TSLP abrogated this inhibition and induced steroid resis

31 chemokines and cytokines, such as CCL17 and TSLP in AD, and CCL20 and IL-19 in psoriasis.

32 our controls were immunostained for CD1c and TSLP receptor (TSLPR).

33 filtrating pathogenic effector Th2 cells and TSLP.

34 elial cell-intrinsic IKKalpha expression and TSLP in regulating ILC3 responses required to maintain i

35 To determine whether variations in FLG and TSLP genotype corresponded to differences in treatment u

36 Evaluation of FLG and TSLP genotypes.

37 ficant correlation between EET formation and TSLP expression (P = 0.02) as well as psoriasin expressi

38 circulating in patients with active LCH, and TSLP and TGF-beta are potential drivers of Langerhans-li

39 TRAIL regulates MID1 and TSLP, inflammation, fibrosis, smooth muscle hypertrophy,

40 Lung tissue histology, neutrophils and TSLP, TNF-alpha, IFN-beta and IFN-lambda mRNA were exami

41 Both OX40L and TSLP have been implicated in the negative regulation of

42 once or twice to evaluate IL-33 release and TSLP expression in the lung.

43 CCL11, CCL20, IL-5, IL-13, IL-25, TGFB, and TSLP.

44 We inoculated 6-d-old BALB/c (wild-type) and TSLP receptor-knockout mice with sham HeLa cell lysate o

45 BALB/c WT and TSLP receptor-deficient (TSLPR(-/-) ) mice were challeng

46 Limited ZsG and TSLP mRNA was observed in bone marrow-derived mast cells

47 An anti-TSLP antibody abrogated airway hyperresponsiveness, infl

48 An anti-TSLP antibody abrogates all pathologic features of asthm

49 knockout (KO), or WT mice receiving an anti-TSLP neutralizing antibody were infected with the RSV st

50 onal antibody therapies (anti-OX40L and anti-TSLP) on Treg frequency using a human model of allergic

51 esults from emerging clinical trials of anti-TSLP agents used for the treatment of a variety of infla

52 s included the anti-IL-33 receptor ST2, anti-TSLP, or both.

53 Whether anti-TSLP therapeutics will have clinical value cannot be det

54 Because TSLP shares signaling components with IL-7, a cytokine i

55 bly, there was gene-gene interaction between TSLP and IL4 SNPs (P = .0074).

56 Alternatively, biologics blocking TSLP, IL-33, IL-4 and IL-13, or IgE may help to achieve

57 t blockade of IL-1 signaling suppresses both TSLP and IL-23 expression and ameliorates skin inflammat

58 ence of IL-4, renders DCs responsive to both TSLP and IL-7.

59 ffector of type 2 immune responses driven by TSLP and suggests that dysregulation of this innate syst

60 siveness 3 weeks post-challenge as judged by TSLP receptor levels in 24-hour cultures.

61 d lung homing of HPCs may be orchestrated by TSLP and IL-33 through an IL-13-dependent axis.

62 allergen might be driven at least in part by TSLP.

63 vator of transcription (STAT) 5 signaling by TSLP.

64 cer metastasis, implying that the pre-B cell-TSLP axis can be an attractive therapeutic target.

65 Contrary to our expectations, circulating TSLP was not significantly associated with eczema, aller

66 is the role of keratinocyte-derived cytokine TSLP and Langerhans cells (LCs).

67 aR, and was dependent on the innate cytokine TSLP and TGF-beta.

68 ence of this response on the innate cytokine TSLP.

69 in DC induced by the Th2-promoting cytokine TSLP, as well as the production of IL-13, IL-4, and IL-5

70 The cytokine TSLP has been shown to be a key factor in maintaining im

71 athelicidin LL-37, psoriasin) and cytokines (TSLP, IL-25, IL-32, IL-33) were elevated in EoE as compa

72 We detected TSLP in 33% of 236 children for whom plasma samples were

73 at 8 h (P < 0.05 to P < 0.0001 vs. diluent); TSLP was undetectable; IL-10, IL-17A, and IL-33 were unc

74 ice and recombinant TRAIL induced esophageal TSLP expression in vivo in the absence of allergen.

75 Endogenous and exogenous TSLP increased Alt-Ext-induced IL-33 release into BALF,

76 Finally, TSLP was required for maximal ILC2 gene expression in re

77 First, TSLP downregulated surface expression of bone marrow (BM

78 BAL fluid TSLP levels correlated (r = 0.74) with steroid resistanc

79 For TSLP-WDR36 region, rs3806932 (G allele protective agains

80 wing that DCs are primed in human asthma for TSLP-driven induction of both Th2 and Th9 cells.

81 IL-7Ralpha expression on DCs is critical for TSLP responsiveness and that IL-4 can upregulate IL-7Ral

82 haracterized by high receptor expression for TSLP, IL-33, and IL-25 further supports a role for these

83 llenge on expression levels of receptors for TSLP (thymic stromal lymphopoietin receptor [TSLPR] and

84 2 intracellular cytokines, and receptors for TSLP, IL-3, and eotaxin in blood, bone marrow, and sputu

85 ndings indicate a novel mechanistic role for TSLP and CD11c-expressing IMs in the development of acut

86 These results demonstrate a role for TSLP and IL-25 in the atopic march from skin sensitizati

87 cancer and establish a fundamental role for TSLP and Th2 cells in tumor immunity against early-stage

88 TSLP receptor (TSLPR), yet a direct role for TSLP in CD8 T cell immunity in the mucosa has not been d

89 ent studies have found an expanding role for TSLP in inflammatory diseases and cancer.

90 This work also demonstrates a new role for TSLP in promoting type 2 responses directly in the lung.

91 ) that are both necessary and sufficient for TSLP-mediated T(H)2-cell differentiation and airway infl

92 t BAC appears to be a faithful surrogate for TSLP expression, particularly in keratinocytes and medul

93 of TSLP to generate a stable dimerized form, TSLP (29-124 + 131-159), in NPs.

94 ide bonds and presented as a dimerized form, TSLP (29-124 + 131-159).

95 identified four cytokines (IL-6, IFN-gamma, TSLP and TGF-beta) that did not signal via the common ga

96 first evidence implicating roles for hepatic TSLP signaling, type 2 immunity, and eosinophilia in med

97 of IL5 and CPA3, were differentiated by high TSLP and IL13 in group III.

98 However, TSLP, IL-33, and IL-25 all regulate a broad spectrum of

99 We incubated recombinant human TSLP with NP extracts, and determined the protein sequen

100 In humans, TSLP level has been found to be elevated in the lungs of

101 Our results identify TSLP as a novel player within the complex psoriasis cyto

102 stressed lung epithelial cells (IL25, IL33, TSLP) to DEP-induced asthma severity remains poorly unde

103 patients had the highest expression of IL5, TSLP, and CCL26 and genes associated with tissue remodel

104 , we will highlight major recent advances in TSLP biology, along with results from emerging clinical

105 re attenuated by anti-IL-33 treatment and in TSLP receptor-knockout mice.

106 dies revealed a dual functionality of LCs in TSLP-promoted T(FH) and T(H)2 differentiation in AD path

107 SNPs in TSLP may affect asthma risk through up-regulating TSLP m

108 of asthma-related genes documenting SNPs in TSLP, GSDMB, IL33, HLA-DQB1, C11orf30, DEXI, CDHR3, and

109 Increased TSLP and TGF-beta levels were detected in patients with

110 fluid from asthmatic patients had increased TSLP but not IL-7 levels.

111 ILC2s from asthmatic patients with increased TSLP levels were steroid resistant, which was reversed b

112 f the IL-33 receptor paradoxically increases TSLP production, which stimulates the emergence of IL-9(

113 Indeed, TSLP can condition dendritic cells to initiate type 2 re

114 and ST2 deficiency decreased Alt-Ext-induced TSLP expression in the lung.

115 ly, calcipotriol plus 5-FU treatment induced TSLP, HLA class II, and natural killer cell group 2D (NK

116 Moreover, the short isoform TSLP ameliorates experimental colitis in mice and preven

117 xpression of inflammatory factors NF-kappaB, TSLP, TNF-alpha, and differentiation marker K10 by 94%-9

118 on of Th2 and Th1 cells induces keratinocyte TSLP expression.

119 We further prove that CRLF2-ligand TSLP boosts the direct binding of active PTPN11 to wtRAS

120 nnate cytokine thymic stromal lymphopoietin (TSLP) acting on mast cells to generate PGD2 and facilita

121 nnate cytokine thymic stromal lymphopoietin (TSLP) and also induced another innate cytokine, IL-33.

122 Thymic stromal lymphopoietin (TSLP) and calpain 14 (CAPN14) genetic variations contrib

123 d increases in thymic stromal lymphopoietin (TSLP) and GM-CSF in primary tracheal epithelial cells is

124 sly, driven by thymic stromal lymphopoietin (TSLP) and IL-23, respectively.

125 tokines IL-33, thymic stromal lymphopoietin (TSLP) and IL-25 in the activation of ILC2s, but the sour

126 Thymic stromal lymphopoietin (TSLP) and IL-33 are considered important initiators of t

127 gnal mediators thymic stromal lymphopoietin (TSLP) and IL-33 are consistently associated with adaptiv

128 Both thymic stromal lymphopoietin (TSLP) and IL-33 levels were increased 12 hours after inf

129 ased levels of thymic stromal lymphopoietin (TSLP) and IL-5 in the skin.

130 Thymic stromal lymphopoietin (TSLP) and IL-7 are related cytokines that mediate growth

131 th recombinant thymic stromal lymphopoietin (TSLP) and TRAIL.

132 ent as well as thymic stromal lymphopoietin (TSLP) and transforming growth factor beta (TGF-beta) pla

133 25, IL-33, and thymic stromal lymphopoietin (TSLP) are associated with FA, and mAbs to these cytokine

134 teractions and thymic stromal lymphopoietin (TSLP) are important in the induction and maintenance of

135 l induction of thymic stromal lymphopoietin (TSLP) at a distant site leads to robust antitumor immuni

136 f secretion of thymic stromal lymphopoietin (TSLP) by cancer cells.

137 rproduction of thymic stromal lymphopoietin (TSLP) by IECs, which negatively regulated IL-22 producti

138 Thymic stromal lymphopoietin (TSLP) has emerged as an important cytokine in the pathog

139 , the cytokine thymic stromal lymphopoietin (TSLP) has recently been shown as a factor in maintaining

140 Thymic stromal lymphopoietin (TSLP) is a cytokine produced mainly by epithelial cells

141 Thymic stromal lymphopoietin (TSLP) is a cytokine with pleiotropic functions in the im

142 Thymic stromal lymphopoietin (TSLP) is a type I cytokine that plays a central role in

143 Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine that is importan

144 Thymic stromal lymphopoietin (TSLP) is an epithelium-derived cytokine that induces a r

145 RATIONALE: Thymic stromal lymphopoietin (TSLP) is known to be elevated and truncated in nasal pol

146 Thymic stromal lymphopoietin (TSLP) is known to be elevated and truncated in nasal pol

147 , skin-derived thymic stromal lymphopoietin (TSLP) mediates progression from eczema to asthma.

148 ression of the thymic stromal lymphopoietin (TSLP) proinflammatory cytokine.

149 Thymic stromal lymphopoietin (TSLP) released after antigenic stimulation of allergic a

150 , resulting in thymic stromal lymphopoietin (TSLP) secretion and a cutaneous T-helper 2 allergic resp

151 with IL-7 and thymic stromal lymphopoietin (TSLP), 2 ligands of IL-7 receptor alpha.

152 25, IL-33, and thymic stromal lymphopoietin (TSLP), are elaborated by sinus epithelial cells in respo

153 sion levels of thymic stromal lymphopoietin (TSLP), cathelicidin, proteases, that is, the kallikreins

154 nd 26 (CCL26), thymic stromal lymphopoietin (TSLP), Charcot-Leyden crystal (CLC), C-C motif chemokine

155 , IL-7, IL-12, thymic stromal lymphopoietin (TSLP), IL-25, and IL-33).

156 ived cytokines thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 are central regulators of type 2

157 okines such as thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 may drive the progression from a

158 e in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar

159 mRNA for sHBEC thymic stromal lymphopoietin (TSLP), IL33, POSTN, and IL25 and downstream targets in s

160 n synergy with thymic stromal lymphopoietin (TSLP), in airway inflammation, antiviral activity, and l

161 rived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled de

162 ied that human thymic stromal lymphopoietin (TSLP), previously shown to be induced during skin inflam

163 nes, IL-33 and thymic stromal lymphopoietin (TSLP), to the observed asthma-like phenotype have not be

164 5), IL-33, and thymic stromal lymphopoietin (TSLP), which nonredundantly activated resident innate ly

165 e induction of thymic stromal lymphopoietin (TSLP).

166 atory cytokine thymic stromal lymphopoietin (TSLP).

167 33), IL-25 and thymic stromal lymphopoietin (TSLP).

168 25), IL-33 and thymic stromal lymphopoietin (TSLP).

169 33 (IL-33) and thymic stromal lymphopoietin (TSLP).

170 via CXCL12 and thymic stromal lymphopoietin (TSLP)/IL-3-dependent upregulation of CXCR4.

171 13, IL-31, and thymic stromal lymphopoietin (TSLP); pro-inflammatory cytokines, such as IL-1beta, IL-

172 tokines (e.g., thymic stromal lymphopoietin [TSLP]) activating human basophils remains controversial.

173 33, IL-25, and thymic stromal lymphopoietin [TSLP]) and mast cell mediators (prostaglandin D2 [PGD2])

174 ays (ie, IL22, thymic stromal lymphopoietin [TSLP], CCL22, and CCL26).

175 2 innate lymphoid cells compared with mature TSLP.

176 A metabolite TSLP (29-130 + 131-159) strongly activated myeloid dendr

177 enerated a heterodimeric unstable metabolite TSLP (29-130 + 131-159).

178 f patients with asthma, and in mouse models, TSLP can promote type 2 airway inflammation, primarily t

179 Moreover, TSLP-induced immunity also blocked early stages of pancr

180 s study the development of a reporter mouse (TSLP-ZsG) in which a ZsGreen (ZsG)-encoding construct ha

181 king ST2, we demonstrated that IL-33 and not TSLP was necessary to drive exacerbations.

182 This novel TSLP/mDC/Th9 axis operates through a distinct, OX40L-ind

183 In contrast, the presence or absence of TSLP minor alleles did not affect asthma risk in subject

184 fications control the functional activity of TSLP in humans and overproduction of TSLP may be a key t

185 We then tested the immune activity of TSLP isoforms both in vitro and in vivo.

186 udy was to provide a mechanistic analysis of TSLP-mediated type 2 airway inflammation METHODS: To dis

187 diately at the translation initiating ATG of TSLP.

188 We suggest that the capacity of TSLP to both induce Th2 differentiation and to be induce

189 Target cells of TSLP in Th2 responses include CD4 T cells and dendritic

190 s have also been shown to be target cells of TSLP.

191 expressing IMs or by selective deficiency of TSLP receptor signaling in these cells.

192 in the airways, and conditional deletion of TSLP receptor and adoptive transfer were used to identif

193 We have solved the dilemma of TSLP being both homeostatic and inflammatory.

194 ied human basophils to measure the effect of TSLP on degranulation, expression of activation markers

195 this study was to investigate the effect of TSLP stimulation on human basophil function.

196 verlapping but partially distinct effects of TSLP and Der p allergen pathways, showing that DCs are p

197 Th2 cells mediated the antitumor effects of TSLP, challenging the notion that Th2 cells only promote

198 treatment blocks MC903-induced expression of TSLP and reverses impaired keratinocyte differentiation.

199 za infection induces the early expression of TSLP by lung epithelial cells with multiple consequences

200 were correlated with decreased expression of TSLP in BAL (P = 7.9 x 10(-11) and 5.4 x 10(-4) , respec

201 ough it has been reported that expression of TSLP receptor (TSLPR) on CD4 T cells is required for OVA

202 Expression of TSLP, IL33, and POSTN mRNA was increased in sHBECs in as

203 Levels of the cleaved active form of TSLP were increased in nasal polyps from patients with A

204 e protein sequence of the truncated forms of TSLP using Edman protein sequencing and matrix-assisted

205 -alpha and IL-4/IL-13 are potent inducers of TSLP expression by keratinocytes and that local activati

206 nhaled antigen through combined induction of TSLP, IL-33, and OX40 ligand and that this can lead to s

207 were treated with TSLP plus ACh, instead of TSLP or ACh alone.

208 Indeed, targeting of the long isoform of TSLP at the C-terminal portion, which is common to both

209 The long isoform of TSLP is proinflammatory and is only expressed during inf

210 of the relationship between plasma levels of TSLP to allergic sensitization and recurrent wheezing wa

211 tumors exposed to high circulating levels of TSLP were arrested at an early adenoma-like stage and we

212 As such, the loss of TSLP expression in cancer cells alone or TSLPR deficienc

213 Loss of TSLP receptor (TSLPR) signaling specifically in regulato

214 The main mechanism of TSLP profibrotic effects is not as yet fully understood,

215 mation METHODS: To dissect the mechanisms of TSLP-mediated type 2 responses, mice were treated with T

216 y in the respiratory tract and modulation of TSLP levels may promote long-term CD8 T cell immunity in

217 Additionally, neutralization of TSLP significantly attenuated the RSV-induced IL-13-prod

218 vity of TSLP in humans and overproduction of TSLP may be a key trigger for the amplification of type

219 oyed: (1) triggered by the overproduction of TSLP through topical application of MC903, and (2) induc

220 This Review provides an overview of TSLP, IL-33, and IL-25 and the development of blocking a

221 re nor the role of the truncated products of TSLP has been studied.

222 volved in the tissue-selective regulation of TSLP transcription in epidermal keratinocytes and IEC.

223 n attenuated the IL-1beta-induced release of TSLP and GM-CSF, suggesting that the ability of PKM2 to

224 In this study we investigated the role of TSLP and IL-33 in the recruitment of progenitor cells to

225 While the role of TSLP in type 2 immune responses has been investigated ex

226 at should be considered in future studies of TSLP-dependent contact sensitization and skin immune res

227 from the C terminus of the longer subunit of TSLP to generate a stable dimerized form, TSLP (29-124 +

228 ggest the potential therapeutic targeting of TSLP during severe RSV infection.

229 e rate-limiting enzymes in the truncation of TSLP between residues 130 and 131 and generated a hetero

230 investigate the mechanisms of truncation of TSLP in NPs and the function of the truncated products.

231 er (GC) response were crucially dependent on TSLP in both the MC903 model and the OVA sensitization m

232 mmation in Il17ra(-/-) mice was dependent on TSLP, but not the other alarmins IL-25 and IL-33.

233 d they should lead to mechanistic studies on TSLP profibrotic signaling.

234 Abs to IL-33 or recombinant IL-33, IL-25, or TSLP.

235 The inability to detect IL-33 or TSLP, or to neutralize their activity, suggested a uniqu

236 nalyses was the number of FLG LOF alleles or TSLP SNPs rather than the absolute presence or absence o

237 cted with anti-IL-25, IL-33 receptor, and/or TSLP mAbs before initial oral gavage with MCT/EW to supp

238 monary accumulation of IL33, but not IL25 or TSLP or other features of allergic disease.

239 ction of an mAb to IL-25, IL-33 receptor, or TSLP strongly inhibited FA development.

240 sfunction, itch, and dermatitis via the PAR2-TSLP pathway.Journal of Investigative Dermatology accept

241 Whole nasal polyp TSLP mRNA expression correlated strongly with mRNA encod

242 but not of PI3K or JAK-signaling, prevented TSLP-induced RAS-GTP boost.

243 In vitro, ASCs produced TSLP that supported ILC2 accumulation and activation.

244 tracts generated 2 major truncated products, TSLP (residues 29-124) and TSLP (131-159).

245 ocytes and that LIGHT could directly promote TSLP expression in these cells.

246 Recombinant TSLP induced PGD2 generation by cultured human mast cell

247 Injection of recombinant TSLP also induced scratching behavior in the SPF NC/Tnd

248 may affect asthma risk through up-regulating TSLP mRNA expression or protein secretion.

249 sHBEC TSLP mRNA expression was strongly associated with sDC OX

250 In human subjects TSLP is present in 2 isoforms, short and long.

251 tion disrupted the role of D6 in suppressing TSLP induction by KLK5 in HaCat cells.

252 interest in developing biologics that target TSLP, IL-33, and IL-25.

253 riers in allergic inflammation and targeting TSLP-mediated signalling is considered an attractive the

254 esign of therapeutic interventions targeting TSLP in asthma.

255 These findings support the concept that TSLP plays a role in the development of fibrosis, and th

256 We demonstrate that TSLP enhances human CD14(+) monocyte CCL17 production in

257 Together, our findings demonstrate that TSLP potently induces immunity directed against early st

258 We also discovered that TSLP is expressed by the breast tumor cells themselves a

259 We found that TSLP synergized with CD40 ligand to promote DC activatio

260 temic infection models, we hypothesized that TSLP spatially and nonredundantly supports the developme

261 ivated Th2 cells raises the possibility that TSLP may be involved in a positive feedback loop to enha

262 The authors also report that TSLP is able to activate fibrocytes, probably by inducin

263 Shin et al. report that TSLP may also play a role in the pathogenesis of keloids

264 We showed that TSLP can directly promote T(H)2-cell differentiation in

265 We showed that TSLP isoforms are responsible for 2 opposite immune func

266 Taken together, these data suggest that TSLP uniquely participates in local immunity in the resp

267 Our results suggest that TSLP-mediated activation of human nasal mucosal CD1c(+)

268 The TSLP isoform ratio is altered during several inflammator

269 n is shaped by counterregulation between the TSLP/type 2 and IL-23/type 17 axes.

270 Activated CD8 T cells express the TSLP receptor (TSLPR), yet a direct role for TSLP in CD8

271 transcription factors and DBS present in the TSLP promoter region are differentially used in intestin

272 r protein 1 (AP1), STAT, and Smad DBS in the TSLP promoter region.

273 cognate DNA-binding sequence(s) (DBS) in the TSLP promoter regulatory region.

274 tor 2 signaling is involved in mediating the TSLP/type 2 axis, whereas skin bacteria are engaged in i

275 vestigate the differential expression of the TSLP isoforms and discern their biological implications

276 matory or microbial stimuli and binds to the TSLP receptor (TSLPR) complex, a heterodimer composed of

277 Using the TSLP-ZsG reporter mouse, we show that TNF-alpha and IL-4

278 Then, TSLP supported peripheral survival and proliferation of

279 uced exacerbation also increased lung tissue TSLP (P < 0.05).

280 ions including the regulation of lung tissue TSLP, TNF-alpha, IFN-beta and IFN-lambda.

281 Pre-exposure to TSLP and IL-33 primed the migration of HPCs to a potent

282 cluding cytokine production and migration to TSLP and IL-33, were assessed in vitro.

283 rine basophils have been shown to respond to TSLP independently of IL-3 by increasing functional thym

284 Basophils responded to TSLP at a similar magnitude and potency as the well-desc

285 he TLR4 agonist LPS, their responsiveness to TSLP is poorly defined.

286 rine ex vivo splenic DCs are unresponsive to TSLP, as they fail to phosphorylate STAT5, but in vitro

287 ated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU)

288 tigated the functional activity of truncated TSLP using a PBMC-based bioassay.

289 n of human lung epithelial cells upregulated TSLP and IL-33 expression.

290 with IL-3 +/- anti-IgE were coincubated with TSLP, IL-33, or IL-25.

291 ated with asthma) showed no correlation with TSLP expression levels.

292 Incubation with TSLP and IL-33 stimulated significant production of IL-5

293 -6); odds ratio [OR], 1.87), moderately with TSLP (P = 1.5 x 10(-4); OR, 1.43), and nominally with CA

294 lood-derived mast cells were stimulated with TSLP in vitro to assess PGD2 generation.

295 In vitro stimulation with TSLP primed basophil migration to eotaxin and induced ra

296 (FLG) loss-of-function mutation, those with TSLP variation were more likely to have less-persistent

297 ted type 2 responses, mice were treated with TSLP and antigen to evaluate cellular immune responses.

298 s further enhanced when DC were treated with TSLP plus ACh, instead of TSLP or ACh alone.

299 Treatment with TSLP reconstituted hallmark features of EoE in TRAIL(-/-

300 tween EoE-predisposing polymorphisms (within TSLP, LOC283710/KLF13, CAPN14, CCL26, and TGFB) and impl